We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord

Ticker
AXSM

Price
100.69
Stock movement up
+0.15 (0.13%)
Company name
Axsome Therapeutics Inc
Exchange
(NASDAQ
,
Currency
USD
)
Sector
Healthcare >
Biotechnology
Markedsværdi
5.85B
Ent værdi
5.99B
Pris/omsætning
17.27
Pris/bog
62.92
Udbytte afkast
-
Udbyttevækst
-
Vekst år
-
FCF-udbetaling
-
Efterfølgende P/E
-
Fremtidig P/E
148.39
PEG
-
EPS-vekst
35.53%
1 års afkast
29.75%
3 års afkast
38.33%
5 års afkast
8.20%
10 års afkast
-
Senest opdateret: 2025-09-12

UDBYTTE

AXSM betaler ikke udbytte

VÆRDIANSÆTTELSE

Værdiansættelsesforhold

Loading...
Værdiansættelsesforhold-data
Efterfølgende P/E-
Pris til OCF-
Pris til FCF-
Pris til EBITDA-
EV i forhold til EBITDA-

Værdiansættelse (salg/bogført værdi)

Loading...
Værdiansættelse (salg/bogført værdi)-data
Pris til omsætning17.27
Pris til egenkapital62.92
EV i forhold til salg17.69

ØKONOMI

Pr. aktie

Loading...
Data pr. aktie
Aktuelt antal aktier49.90M
EPS (TTM)-6.46
FCF pr. aktie (TTM)-2.76

Resultatopgørelse

Loading...
Resultatopgørelse-data
Omsætning (TTM)338.46M
Bruttofortjeneste (TTM)306.46M
Driftsindkomst (TTM)-307.47M
Nettoindkomst (TTM)-310.95M
EPS (TTM)-6.46
EPS (1 år frem)0.79

Marginer

Loading...
Marginer-data
Bruttomargin (TTM)90.55%
Driftsmargin (TTM)-90.84%
Fortjenstmargin (TTM)-91.87%

Balance

Loading...
Opret en gratis konto eller log ind for at få adgang til dette diagram
Balancedata
Kontanter327.34M
Nettotilgodehavender124.10M
Omsætningsaktiver i alt479.11M
Goodwill12.04M
Immaterielle aktiver48.50M
Ejendomme, anlæg og udstyr6.41M
Sum aktiver561.46M
Kreditor64.25M
Kortfristet/nuværende langsigtet gæld192.30M
Summen af kortfristede forpligtelser196.19M
Sum gæld468.56M
Aktionærernes egenkapital92.90M
Materielle nettoaktiver0.00

Likviditet

Loading...
Opret en gratis konto eller log ind for at få adgang til dette diagram
Kontantstrøm-data
Likviditet fra driften (TTM)-132.57M
Investeringsudgifter (TTM)307.00K
Fri pengestrøm (TTM)-132.88M
Udbetalt udbytte (TTM)0.00

Finansiel indkomst

Loading...
Opret en gratis konto eller log ind for at få adgang til dette diagram
Data om finansiel indkomst
Egenkapitalafkast-334.73%
Afkast af aktiver-55.38%
Afkast af investeret kapital-112.74%
Kontant afkast af investeret kapital-48.18%

INFORMATION OM AKTIER

Aktiediagram

Loading...
Aktiekurs-data
Åbning116.99
Daglig høj117.29
Daglig lav114.49
Daglig volumen456K
Højeste gennem alle tider137.75
1 års analytiker estimat176.95
Beta0.51
EPS (TTM)-6.46
Udbytte pr. aktie-
Ex-div dato-
Næste dato for resultatpræsentation10 Nov 2025

Nedsidepotensial

Loading...
Nedsidepotensial-data
AXSMS&P500
Nuværende prisfald fra top notering-14.96%-1.46%
Højeste prisfald-86.65%-56.47%
Højeste efterår dato27 Dec 20189 Mar 2009
Gennemsnitlig fald fra toppen-42.25%-10.99%
Gennemsnitlig tid til nyt højdepunkt45 days12 days
Maks. tid til nyt højdepunkt1280 days1805 days

iO Charts is a Seeking Alpha partner

iO Charts is a Seeking Alpha partner

OPLYSNINGER OM VIRKSOMHEDEN
AXSM (Axsome Therapeutics Inc) company logo
Markedsværdi
5.85B
Markedsværdi kategori
Mid-cap
Beskrivelse
Axsome Therapeutics, Inc., a biopharmaceutical company, develops and delivers novel therapies for the management of central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist, sigma-1 receptor agonist, aminoketone, and CYP2D6 inhibitor indicated for the treatment of major depressive disorder in adults; Sunosi (solriamfetol), a dopamine and norepinephrine reuptake inhibitor, trace amine-associated receptor 1 agonist, and 5-HT1A agonist indicated for the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea; and Symbravo (MoSEIC meloxicam rizatriptan), or AXS-07, a rapidly absorbed, multi-mechanistic, selective COX-2 inhibitor, and 5-HT1B/1D agonist indicated for the acute treatment of migraine with or without aura. It also develops AXS-05 (dextromethorphan-bupropion), an investigational N-methyl-D-aspartate receptor antagonist, which has completed Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-12 (reboxetine), a highly selective and potent norepinephrine reuptake inhibitor and cortical dopamine modulator, which has completed Phase III trial to treat narcolepsy; AXS-14 (esreboxetine), a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and Solriamfetol, a dopamine and norepinephrine reuptake inhibitor, which is in Phase III trial for treating attention deficit hyperactivity, major depressive, binge eating, and excessive sleepiness associated with shift work disorder. The company has a research collaboration agreement with Duke University for evaluating AXS-05 in a Phase 2 clinical trial in smoking cessation. Axsome Therapeutics, Inc. was incorporated in 2012 and is based in New York, New York.
Personale
846
Investor relationer
-
SEC-indsendelser
Adm. direktør
Herriott Tabuteau
Land
USA
By
New York
Aktietype
Common stock
CCC-status
-
Utbyttefrekvens
-
ARRANGEMENTER OG PRÆSENTATIONER
ArrangementerPræsentationer
Loading...

iO Charts is a Seeking Alpha partner

iO Charts is a Seeking Alpha partner

FORSTÅ FORRETNINGEN
Loading...